Non-linear pharmacokinetics of MDMA ('ecstasy') in humans

British Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2000, Pages 104-109

  De La Torre, Rafael ^a,c   Farre M ^a   Ortuno J ^a   Mas, M ^a   Brenneisen, R ^b   Roset, P N ^a   Segura, J ^a   Cami, J ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITY OF BERN   (Switzerland)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Ecstasy; Humans; MDMA; Pharmacokinetics

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; LIVER ENZYME;

ADULT; ARTICLE; BLOOD SAMPLING; BODY FLUID; CLINICAL TRIAL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIVER METABOLISM; MALE; PRIORITY JOURNAL; URINALYSIS;

3,4-METHYLENEDIOXYAMPHETAMINE; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; CROSS-OVER STUDIES; DEOXYEPINEPHRINE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALLUCINOGENS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; METABOLIC CLEARANCE RATE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PILOT PROJECTS; TIME FACTORS;

EID: 0033967676     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00121.x     Document Type: Article

References (19)

1. 1 Nichols DE. Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoactive Drugs 1986; 18: 305-313.
2. 2 Henry JA, Jeffregsand KS, Loumberg W. Toxicity and deaths from 3, 4-methylenedioxymethamphetamine. Lancet 1992; 340: 384-387.
3. 3 Spanos LJ, Yamamoto BK. Acute and subchronic effects of methylenedioxy methamphetamine (±MDMA) on locomotion and serotonin syndrome in rat. Pharmacol Biochem Behav 1989; 32: 835-840.
4. 4 Burdkin J, Malyala A, Nash JF. Effect of acute monoamine depletion on 3, 4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1993; 45: 647-653.
5. 5 Green AR, Goodwin GM. Ecstasy and neurodegeneration. Br Med J 1996; 312: 1493-1494.
6. 6 Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3.,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 1996; 73: 103-107.
7. 7 Verebey K, Alrazi J, Jaffe JH. The complications of 'Ecstasy' (MDMA). JAMA 1988; 259: 1649-1650.
8. 8 Helmlin HJ, Bracher K, Bourquin D, Bonlanthen D, Brenneisen R. Analysis of 3,4-methylene-dioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 1996; 20: 432-440.
9. 9 Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA ('ecstasy') induces vasopresin secretion. Lancet 1998; 351: 1784.
10. 10 Maurer HH. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther Drug Monit 1996; 18: 465-470.
11. 11 Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxyamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47: 1151-1156.
12. 12 Mas M, Farré M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-Methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136-145.
13. 13 Camí J, Mas M, Farré M, et al. Pharmacological effects of MDMA in humans: dose-finding pilot study. In Problems of Drug Dependence ed Harris LS. Nat Inst Drug Abuse Res Mon 178, Washington DC. Supt of Doc, US Gov Prin Off, DHHS (NIH 98-4305): 290, 1998.
14. 14 Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextrometorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985; 38: 618-624.
15. 15 Ortuño J, Pizarro N, Farré M, et al. Quantification of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorous detection (GC/NPD). J Chromatogr B 1999; 723: 221-232.
16. 16 Shumaker RC. A basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17: 331-348.
17. 17 Lin LY, Di Stefano EW, Schmitz DA, et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metabol Disp 1997; 25: 1059-1064.
18. 18 Wu D, Otton V, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53: 1605-1612.
19. 19 Lin LY, Fujimoto M, Di Stefano EW, Schmitz DA, Jayasinghe A, Cho AK. Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine. J Pharmacol Exp Ther 1996; 277: 595-603.